OakChart

Collegium Pharmaceutical Inc

COLLHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NASD·Nov 11 • 11:37 AM ET

24.36-0.11 (-0.45%)
2026-11-11 17:38 CET
Market cap
760.41 USD m
Revenue, TTM
815.19 USD m
Net income, TTM
38.17 USD m
Free cash flow, TTM
336.29 USD m
EPS diluted, TTM
0.99
P/E
24.57
Compare

Price

COLL against its 20, 50 and 200-day averages
2050200beatearnings
25.0030.0035.0040.001.1M2.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26COLLclose 24.3620-day 23.6650-day 22.98200-day 32.3524.3652w low

52.0% under the 52-week high of 50.79 on 29 Dec 2025. 52-week low 21.43 on 1 Oct 2026. Last 15 sessions, 19.1% high to low

Profile

COLL
52-week range, 10% of the way up
21.4350.79

Collegium Pharmaceutical, Inc. is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. The firm has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

IndexRUT
Employees423
IPOMay 07, 2015
Beta0.72
ATR, 14d0.94
Rel volume0.41
Short float17.03%
Insider own1.85%
Inst own133.26%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap756.99M
Enterprise Value1.80B
Income38.17M
Sales815.19M
Book/sh9.54
Cash/sh5.30
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees423
IPOMay 07, 2015

Ratios

P/E24.57
Forward P/E3.40
PEG4.60
P/S0.93
P/B2.55
P/C4.60
P/FCF2.25
EV/EBITDA5.02
EV/Sales2.21
Quick Ratio0.87
Current Ratio1.01
Debt/Eq4.07
LT Debt/Eq3.86
Option/ShortYes / Yes

Earnings

EPS (ttm)0.99
EPS next Y7.16
EPS next Q1.92
EPS this Y0.80%
EPS next Y-4.32%
EPS next 5Y0.74%
EPS past 3/5Y- 17.92%
Sales past 3/5Y18.94% 20.28%
EPS Y/Y TTM-34.31%
Sales Y/Y TTM7.68%
EPS Q/Q-28.97%
Sales Q/Q3.33%
EarningsNov 05 BMO
EPS/Sales Surpr.5.56% 0.14%

Ownership

Insider Own1.85%
Insider Trans-2.93%
Inst Own133.26%
Inst Trans-0.51%
ROA2.06%
ROE13.36%
ROIC2.65%
Gross Margin59.05%
Oper. Margin15.43%
Profit Margin4.68%
SMA202.95%
SMA505.99%
SMA200-24.71%
Trades-

Technical

Shs Outstand31.07M
Shs Float30.50M
Short Float17.03%
Short Ratio6.37
Short Interest5.19M
52W High50.79 -52.04%
52W Low21.43 13.67%
Volatility4.92% 3.78%
ATR (14)0.94
RSI (14)56.72
Beta0.72
Rel Volume0.41
Avg Volume815.11K
Volume121,441

Performance

Perf Week2.91%
Perf Month13.14%
Perf Quarter-13.47%
Perf Half Y-30.14%
Perf YTD-47.39%
Perf Year-45.67%
Perf 3Y-0.49%
Perf 5Y21.07%
Perf 10Y39.20%
Recom1.38
Target Price44.88
Prev Close24.47
Price24.36
Change %-0.45%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 23, 2026InitiatedOOppenheimerOutperform$50+105.3%
Sep 09, 2026ResumedTTruistBuy$49+101.2%
Sep 09, 2026InitiatedLLeerink PartnersOutperform$45+84.7%
Dec 09, 2025InitiatedBBarclaysOverweight$58+138.1%
Jan 10, 2025UpgradeNNeedhamHold → Buy$46+88.8%
Jul 30, 2024UpgradeHH.C. WainwrightNeutral → Buy$47+92.9%
Jun 07, 2024UpgradeJJefferiesHold → Buy$41 → $44+80.6%
May 10, 2024DowngradePPiper SandlerOverweight → Neutral$39+60.1%
May 10, 2024DowngradeNNeedhamBuy → Hold
Jan 04, 2024DowngradeJJefferiesBuy → Hold$30 → $37+51.9%

Peers

Mkt cap
TickerCompanyMkt cap
SUPNSupernus Inc6.09B
PCRXPacira BioSciences Inc1.46B
AMRXAmneal Pharmaceuticals Inc7.62B
INDVIndivior Pharmaceuticals Inc5.97B
ZVRAZevra Therapeutics Inc714.66M
AYTUAytu BioPharma Inc19.78M
XERSXeris Biopharma Holdings Inc2.98B
TLPHTalphera Inc55.02M
VRTXVertex Pharmaceuticals Inc136.69B
HRTXHeron Therapeutics Inc66.25M

Insider trading

latest 14 of 27
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Dreyer ScottFormer OfficerSep 30 '26Proposed Sale22.0027,419603,321Sep 30 03:52 PM
Fallon John A.Former DirectorJul 17 '26Proposed Sale35.7313,920497,429Jul 17 12:08 PM
Fallon John A.Former DirectorJul 15 '26Proposed Sale36.328,095294,010Jul 15 04:07 PM
SANTINI GINODirectorJun 08 '26Option Exercise16.498,700143,463112,483Jun 10 04:10 PM
Freund John GordonDirectorMay 18 '26Sale34.052068183,952May 20 04:05 PM
Freund John GordonDirectorMay 15 '26Option Exercise16.498,700143,46388,099May 18 04:15 PM
Freund John GordonDirectorMay 15 '26Sale34.544,127142,54783,972May 18 04:15 PM
Freund John GordonDirectorMay 18 '26Proposed Sale34.05301,022May 18 04:07 PM
Lurker NancyDirectorMay 13 '26Sale35.974,500161,86118,017May 15 04:05 PM
Freund John GordonDirectorMay 15 '26Proposed Sale34.544,127142,547May 15 10:51 AM
BOHLIN GAREN GDirectorMay 11 '26Option Exercise16.498,700143,46370,959May 13 04:05 PM
BOHLIN GAREN GDirectorMay 11 '26Sale37.188,700323,49162,259May 13 04:05 PM
Lurker NancyDirectorMay 13 '26Proposed Sale35.974,500161,861May 13 12:09 PM
BOHLIN GAREN GDirectorMay 11 '26Proposed Sale37.188,700323,491May 11 11:38 AM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
PJPInvesco Pharmaceuticals ETFAUM: 603.92M
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.39B
PBEInvesco Biotechnology & Genome ETFAUM: 438.02M
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
VXFVanguard Extended Market Index ETFAUM: 30.47B
CALFPacer US Small Cap Cash Cows ETFAUM: 3.86B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B

News

latest 14 of 206
  • Collegium Beats On ADHD Strength, But Pain Erosion And Heavier Spending Keep Earnings Shrinking (Earnings Whispers) +6.29%
  • Collegium Pharmaceutical: Q3 Earnings Snapshot (Associated Press)
  • Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance (GlobeNewswire)
  • Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts (GlobeNewswire)
  • Collegium Needs Jornay And Astaris To Outrun A Fading Nucynta Franchise (Earnings Whispers)
  • Loading…
  • Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire)
  • Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses (GlobeNewswire)
  • Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life (GlobeNewswire)
  • Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Collegium Announces $50 Million Accelerated Share Repurchase Program (GlobeNewswire) +9.53%
  • Collegium Pharmaceutical Inc (COLL) (Q2 2026) Earnings Call Highlights: ADHD Portfolio Surges ... (GuruFocus.com) -18.55%
  • Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press)
  • Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-051.9601.8570.600216.34216.037
2026Q22026-08-061.9201.719-0.464199.88199.634
2026Q12026-05-071.7601.5240.399193.52184.475
2025Q42026-02-262.0402.1390.460205.45206.365
2025Q32025-11-062.2501.8600.839209.36189.124
2025Q22025-08-071.6801.6170.345188180.883
2025Q12025-05-081.4901.4330.074177.76171.954
2024Q42025-02-271.7701.5380.350181.95179.754
2024Q32024-11-071.6101.5920.268159.3155.654
2024Q22024-08-081.6201.4850.522145.28143.945
2024Q12024-05-091.4501.4700.708144.92146.945
2023Q42024-02-221.5801.3780.820149.75147.864
2023Q32023-11-071.3401.2180.530136.71137.275
2023Q22023-08-031.2601.2180.343135.55138.465
2023Q12023-05-041.3201.333-0.508144.77138.366
2022Q42023-02-231.0901.092-0.214129.62125.225

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.2550.144-0.679296.7295.82
2020FY3.7933.7540.761310.02311.22
2021FY2.2633.8421.856276.87332.37
2022FY3.9604.332-0.739463.93459.5
2023FY5.4705.2101.293566.77564.88
2024FY6.4506.1811.857631.45629.25
2025FY7.4207.4701.730780.57781.49
2026FY-7.480--831.96
2027FY-7.156--847.7
2028FY-7.586--861.45
2029FY-10.325--921.25
2030FY-11.333--954.37

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-05714222.21216.4224.3
2026Q4S2026-10-20703223.59217227.89
2026Q4S2026-10-13706223.59217227.89
2026Q4S2026-10-07705224.16221227.89
2026Q4S2026-10-05704224.84221228.81
2026Q4S2026-10-02704224.74221228.81
2026Q4S2026-09-21704225.24221230
2026Q4S2026-09-08604224.64221230
2026Q4S2026-08-06404224.93221.2230
2026Q4S2026-07-25401243.75243.1244.7
2026Q4S2026-07-21411243.75243.1244.7
2026Q4S2026-07-16421243.75243.1244.7
2026Q4S2026-05-18430245.15243.1249.2
2026Q4S2026-05-12530244.81243.1249.2

Estimate history

EPS, annual-2.474-1.187-0.6790.7611.856-0.7391.2931.8571.7350.9914
Period201720182019202020212022202320242025TTM
EPS, quarterly0.2680.350.0740.3450.8390.460.399-0.4640.596
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual28.476280.413296.701310.016276.868463.933566.767631.449780.567815.19
Period201720182019202020212022202320242025TTM
Sales, quarterly159.301181.949177.757188209.361205.449193.52199.878216.339
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual32.77133.26633.67934.61233.65533.84931.86931.4431.70831.072
Period201720182019202020212022202320242025MRQ
Shares, quarterly32.2331.4432.13231.54931.60131.70832.40732.49831.072
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue815.19780.57631.45566.77463.93276.87310.02296.70280.41
Cost of Goods Sold Incl. D&A333.85317.31254.10240.60252.34127.99130.18193.66165.68
Gross Profit481.33463.26377.34326.17211.59148.88179.84103.04114.74
Selling, General and Administrative Excl. Other355.58276.17186.03150.71142.19123.74123.60126.79135.42
Research and Development-0.000.000.001.307.719.7710.348.66
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income125.76187.08191.31175.4669.4025.1456.23-23.75-20.68
Interest Expense76.6282.3173.9783.3463.2121.0128.880.9120.13
Unusual Expense17.6823.4432.7432.0036.087.510.00--
Net Income Before Taxes42.1592.6298.5775.73-28.85-3.3727.58-22.72-39.13
Income Taxes3.9829.7529.3827.58-3.85-74.890.830.000.00
Consolidated Net Income38.1762.8769.1948.16-25.0071.5226.75-22.72-39.13
Net Income From Continuing Operations38.1762.8769.1948.16-25.0071.5226.75-22.72-39.13
Net Income38.1762.8769.1948.16-25.0071.5226.75-22.72-39.13
EPS (Recurring)1.412.152.421.830.011.980.76-0.68-1.19
EPS (Basic, Before Extraordinaries)1.211.982.141.43-0.742.050.78-0.68-1.19
EPS (Diluted)0.991.731.861.29-0.741.860.76-0.68-1.19
EBITDA358.69413.16360.47324.72203.7994.08117.84-7.9590.22
Non-Operating Income (Expense)10.6911.2913.9815.621.050.010.231.941.69
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense37.5733.1125.6021.4418.0717.7121.9116.5313.78
Price To Earnings Ratio24.6824.6812.36204.79-11.2426.33--
Price To Sales Ratio1.052.351.832.271.692.772.272.322.02
Gross Margin59.0559.3559.7657.5545.6153.7758.0134.7340.92
Operating Margin15.4323.9730.3030.9614.969.0818.14-8.00-7.38
Net Margin4.688.0510.968.50-5.3925.838.63-7.66-13.95
Shares Outstanding31.0731.7131.4431.8733.8533.6634.6133.6833.27
Market Capitalization760.41760.41923.971,003.76778.87645.74692.68689.92570.85

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue216.34199.88193.52205.45209.36188.00177.76181.95
Cost of Goods Sold Incl. D&A90.9289.5976.2777.0780.1979.6280.4383.66
Gross Profit125.42110.29117.25128.38129.17108.3897.3298.29
Selling, General and Administrative Excl. Other98.64104.4185.2867.2465.5572.7073.7458.65
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income26.775.8831.9661.1463.6235.6823.5939.64
Interest Expense21.9419.5215.8619.2921.7720.4620.7922.65
Unusual Expense-1.952.181.0716.371.530.581.901.53
Net Income Before Taxes7.91-13.5318.7429.0443.4417.023.1217.27
Income Taxes-13.851.524.2412.0711.935.040.704.73
Consolidated Net Income21.76-15.0514.5016.9631.5111.982.4212.54
Net Income From Continuing Operations21.76-15.0514.5016.9631.5111.982.4212.54
Net Income21.76-15.0514.5016.9631.5111.982.4212.54
EPS (Recurring)0.56-0.420.420.750.870.350.110.38
EPS (Basic, Before Extraordinaries)0.69-0.460.450.541.000.380.080.39
EPS (Diluted)0.60-0.460.400.460.840.340.070.35
EBITDA82.6170.6487.90117.53120.1392.2980.1596.15
Non-Operating Income (Expense)1.132.293.713.563.122.382.231.81
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.8311.448.607.707.758.559.106.00
Price To Earnings Ratio24.6817.7219.2628.8233.7824.3716.1612.36
Price To Sales Ratio1.051.451.662.381.821.631.481.82
Gross Margin57.9755.1860.5962.4961.7057.6554.7554.02
Operating Margin12.382.9416.5229.7630.3918.9813.2721.79
Net Margin10.06-7.537.498.2615.056.371.366.89
Shares Outstanding31.0732.5032.4131.7131.6031.5532.1331.44
Market Capitalization760.411,174.101,050.081,463.591,102.26950.44939.84923.97

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments406.53187.76310.55173.69186.43174.12170.02146.63118.70
Short Term Receivables211.33228.54179.53183.12105.8483.3272.9577.959.97
Inventories40.9135.5632.3346.5017.3915.619.647.821.81
Other Current Assets32.6430.3915.2016.685.884.843.105.123.00
Total Current Assets691.41482.26537.60419.99315.54277.89255.72237.51133.48
Net Property, Plant & Equipment16.2020.1522.0126.3827.1427.3820.909.271.83
Total Investments and Advances1.061.051.052.552.552.550.000.000.10
Intangible Assets815.431,053.73555.57701.16268.72335.9029.5044.260.00
Deferred Tax Assets141.6898.0326.2623.9578.04----
Other Assets20.198.370.820.100.090.120.180.200.16
Total Assets1,685.971,663.591,143.311,174.13692.08643.84306.30291.25135.57
Short Term Debt Incl. Current Port. of LT Debt30.4165.85184.32163.6149.1748.234.491.641.48
Accounts Payable10.663.938.693.494.1910.026.2512.155.68
Income Tax Payable3.308.532.140.00-----
Other Current Liabilities395.67431.20262.77266.62226.21181.21191.03175.3324.32
Total Current Liabilities440.03509.51457.92433.73279.57239.45201.76189.1331.49
Long Term Debt906.02914.06489.96545.56209.58218.3617.119.860.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities29.14--------
Other Liabilities9.1111.180.000.000.000.000.000.680.00
Total Liabilities1,384.301,434.75947.88979.29489.15457.81218.87199.6631.49
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity301.68228.84195.43194.84202.93186.0387.4391.58104.08
Total Shareholders Equity301.68228.84195.43194.84202.93186.0387.4391.58104.08
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity301.68228.84195.43194.84202.93186.0387.4391.58104.08
Total Liabilities & Stockholders Equity1,685.971,663.591,143.311,174.13692.08643.84306.30291.25135.57
Book Value Per Share9.517.286.135.766.035.372.602.753.18
Tangible Book Value Per Share-16.20-26.24-11.30-14.96-1.95-4.331.721.423.18
Full-Time Employees423357197207152234255266250
Price to Book Ratio2.563.945.693.973.103.737.936.245.90
Return on Assets3.754.934.16-2.6810.715.63-7.61-18.33-50.32
Return on Equity23.7032.6224.68-12.5736.7719.57-25.39-39.99-62.65
Return on Invested Capital5.216.057.03-3.3817.346.62-21.74-38.57-71.93
Quick Ratio1.480.881.100.861.071.101.221.214.18
Current Ratio1.570.951.170.971.131.161.271.264.24

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income38.1762.8769.1948.16-25.0071.5226.75-22.72-39.13
Depreciation232.93226.07169.16149.26134.3968.9461.6115.80110.91
Other Funds (Non Cash)62.4762.2848.4257.7635.95-50.3830.8816.5333.06
Funds from Operations288.90325.56259.96253.02136.9490.07119.249.60104.84
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital49.123.76-54.9821.73-12.7113.49-25.3018.1864.55
Cash from Operating Activities338.02329.32204.98274.75124.23103.5693.9427.78169.39
Capital Expenditures-1.73-1.74-1.65-0.46-1.62-1.94-373.77-6.44-24.35
Net Assets From Acquisitions-655.400.00-267.540.00-572.070.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments135.82-61.79-18.57-70.350.000.000.000.000.00
Purchase of Investments-59.32-126.97-111.17-92.350.000.000.000.000.00
Sale Or Maturity of Investments195.1565.1892.6022.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities-521.31-63.53-287.76-70.81-573.69-1.94-373.77-6.44-24.35
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-45.87-19.46-48.95-65.90-1.92-35.157.332.865.34
Repurchase of Common Pref Stock-50.00-25.10-60.02-75.00-14.06-47.860.000.000.00
Sale of Common Pref Stock4.135.6411.079.1012.1512.717.332.865.34
Proceedsfrom Stock Options0.480.000.000.000.000.000.000.00-0.03
Issuance or Reduction of Debt, Net251.80-70.387.52-65.92442.68-50.00281.390.0010.02
Change in Long Term Debt251.80-70.387.52-65.92442.68-50.00281.390.0010.02
Issuance of Long Term Debt864.42565.17313.18235.22517.680.00330.390.0010.02
Reduction of Long Term Debt-612.62-635.56-305.66-301.14-75.00-50.00-49.000.000.00
Net Financing Active Other Cash Flow-27.94-20.40-19.17-8.36-4.04-4.15-2.25-0.82-132.56
Other Financing Activities Uses-27.94-20.40-19.17-8.36-4.04-4.15-2.25-0.82-132.56
Cash from Financing Activities178.00-110.25-60.60-140.18436.72-89.30286.472.04-117.20
Net Change in Cash-5.29155.55-143.3863.76-12.7412.316.6423.3927.84
Free Cash Flow336.29327.58203.33274.29122.61101.6188.4021.34163.91
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow2.545.615.704.696.407.557.9732.253.45
Deferred Taxes & Investment Tax Credit--25.66-26.81-2.15-8.390.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments164.65149.32441.60406.53305.71242.00
Short Term Receivables310.79285.10228.76211.33233.95213.02
Inventories88.20113.2742.7440.9138.0538.15
Other Current Assets48.1260.3332.5632.6436.1656.04
Total Current Assets611.75608.01745.67691.41613.87549.21
Net Property, Plant & Equipment15.2914.4415.6416.2016.6818.17
Total Investments and Advances1.061.061.061.061.051.05
Intangible Assets1,328.431,376.26759.96815.43870.91928.39
Deferred Tax Assets126.25120.77113.57141.68102.4891.97
Other Assets13.1515.2416.0620.192.343.85
Total Assets2,095.942,135.791,651.951,685.971,607.331,592.63
Short Term Debt Incl. Current Port. of LT Debt62.1056.5634.0730.4165.9565.92
Accounts Payable10.439.246.8310.667.6510.89
Income Tax Payable1.841.147.793.300.800.33
Other Current Liabilities528.72522.92386.28395.67378.53387.47
Total Current Liabilities603.09589.86434.97440.03452.93464.61
Long Term Debt1,145.521,161.32895.62906.02870.31885.82
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities19.9640.97-29.14--
Other Liabilities30.9331.738.949.119.2810.00
Total Liabilities1,799.501,823.881,339.531,384.301,332.521,360.42
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity296.44311.91312.42301.68274.81232.21
Total Shareholders Equity296.44311.91312.42301.68274.81232.21
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity296.44311.91312.42301.68274.81232.21
Total Liabilities & Stockholders Equity2,095.942,135.791,651.951,685.971,607.331,592.63
Book Value Per Share9.549.609.649.518.707.36
Tangible Book Value Per Share-33.21-32.75-13.81-16.20-18.86-22.07
Full-Time Employees---423--
Price to Book Ratio2.563.753.485.324.754.05
Return on Assets2.062.574.573.753.602.74
Return on Equity13.3617.6127.4123.7022.9616.16
Return on Invested Capital1.51-1.021.201.402.751.07
Quick Ratio0.870.841.621.481.271.10
Current Ratio1.011.031.711.571.361.18

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income21.76-15.0514.5016.9631.5111.98
Depreciation55.8464.7755.9456.4056.5156.61
Other Funds (Non Cash)9.8815.1611.5025.9311.0612.63
Funds from Operations61.0057.7280.9789.2286.9478.30
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital25.5413.60-23.8533.83-8.50-5.86
Cash from Operating Activities86.5471.3257.11123.0578.4472.44
Capital Expenditures-0.28-0.50-0.27-0.69-0.19-0.07
Net Assets From Acquisitions0.00-655.400.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.00153.311.90-19.38-30.68-2.85
Purchase of Investments0.00-1.99-18.11-39.22-45.24-16.61
Sale Or Maturity of Investments0.00155.3020.0119.8414.5613.76
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.28-502.591.63-20.07-30.87-2.92
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-48.670.481.340.982.29-24.80
Repurchase of Common Pref Stock-50.000.000.000.000.00-25.10
Sale of Common Pref Stock1.330.481.340.982.290.31
Proceedsfrom Stock Options0.900.000.95-1.360.860.00
Issuance or Reduction of Debt, Net-11.26292.25-7.25-21.95-16.15-16.15
Change in Long Term Debt-11.26292.25-7.25-21.95-16.15-16.15
Issuance of Long Term Debt-0.26299.500.00565.170.000.00
Reduction of Long Term Debt-11.00-7.25-7.25-587.12-16.15-16.15
Net Financing Active Other Cash Flow-11.00-0.65-15.43-0.86-0.96-7.43
Other Financing Activities Uses-11.00-0.65-15.43-0.86-0.96-7.43
Cash from Financing Activities-70.93292.09-21.34-21.82-14.82-48.37
Net Change in Cash15.33-139.1837.4081.1632.7521.15
Free Cash Flow86.2670.8356.84122.3678.2572.37
Price to Free Cash Flow2.543.584.025.664.775.73

Revenue breakdown

Belbuca2024: 211.27M 2025: 221.65M
Jornay PM2024: 37.24M 2025: 148.86M
Nucynta ER2024: 75.77M 2025: 80.99M
Nucynta IR2024: 100.74M 2025: 115.31M
Symproic and other2024: 15.10M 2025: 14.45M
Xtampza ER2024: 191.33M 2025: 199.31M
United States2024: 631.45M 2025: 780.57M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3017.03%5.2M30.5M811.98K
2026-10-1516.82%5.4M32.0M767.30K
2026-09-3017.27%5.5M32.0M722.58K
2026-09-1517.82%5.7M31.9M653.87K
2026-08-3119.04%6.1M31.8M565.57K
2026-08-1420.49%6.5M31.8M492.52K
2026-07-3115.96%5.1M31.8M424.24K
2026-07-1516.50%5.2M31.7M447.96K
2026-06-3017.23%5.5M31.7M468.31K
2026-06-1516.84%5.3M31.7M503.08K
2026-05-2917.81%5.7M31.8M531.74K
2026-05-1518.76%6.0M31.8M540.22K
2026-04-3018.59%5.9M31.9M502.45K
2026-04-1518.91%6.0M31.9M519.47K
2026-03-3118.13%5.5M30.5M512.20K
2026-03-1314.02%4.3M30.5M464.57K
2026-02-2715.07%4.6M30.5M453.23K
2026-02-1315.72%4.8M30.4M474.50K
2026-01-3015.69%4.8M30.6M545.71K
2026-01-1518.28%5.6M30.6M510.45K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.509.6013.900.005.9310.000.000.876-0.3290.008
call15.007.2011.500.004.6610.000.000.838-0.3180.009
call17.504.709.000.003.7650.000.000.792-0.2980.011
call20.002.356.604.273.0186.000.000.736-0.2760.013
call22.500.304.702.452.5004.000.000.660-0.2460.014
call25.000.001.551.501.10974.000.000.525-0.1370.016
call30.000.003.700.202.17788.000.000.334-0.1690.014
put12.500.003.400.007.5280.000.00-0.124-0.3240.008
put15.000.003.400.006.0770.000.00-0.163-0.3140.009
put17.500.003.400.304.9162.000.00-0.207-0.2970.011
put20.000.003.501.253.97422.000.00-0.263-0.2740.013
put22.500.003.801.463.2251.000.00-0.340-0.2430.014
put25.000.004.303.302.5922.000.00-0.483-0.1430.015
put30.004.008.007.402.7863.000.00-0.666-0.1660.014

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13G/ASEC
2026-11-10SCHEDULE 13GSEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-29SCHEDULE 13G/ASEC
2026-10-198-KCurrent report2026-10-15SEC
2026-10-08SCHEDULE 13G/ASEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-138-KCurrent report2026-08-12SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-05SCHEDULE 13GSEC
2026-07-31SCHEDULE 13GSEC
2026-07-17144Filing for proposed sale of securities under Rule 144.SEC
2026-07-15144Filing for proposed sale of securities under Rule 144.SEC
2026-06-308-K/A2026-05-12SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-01S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-01S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-204Statement of changes in beneficial ownership of securities2026-05-18SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-183Initial statement of beneficial ownership of securities2026-05-14SEC
2026-05-18144Filing for proposed sale of securities under Rule 144.SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-0500628.58K4
2026-040000
2026-03002.51M2
2026-020000
2026-010000
2025-12001.02M2
2025-11002.86M2

Institutional holders

Manager% owned
BlackRock, Inc.16.78%
Jupiter Topco LLC6.62%
Invesco Ltd.5.80%
FULLER & THALER ASSET MANAGEMENT, INC.5.03%
STATE STREET CORP4.71%
PRINCIPAL FINANCIAL GROUP INC4.65%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/4.33%
VANGUARD CAPITAL MANAGEMENT LLC4.26%
RENAISSANCE TECHNOLOGIES LLC4.21%
EVENTIDE ASSET MANAGEMENT, LLC4.20%

Funds

Fund% owned
Miller Market Neutral Income Fund10.79%
iShares Core S&P Small-Cap ETF6.03%
Fidelity Convertible Securities Fund5.07%
FULLERTHALER BEHAVIORAL SMALL CAP EQUITY4.81%
Eventide Gilead Fund4.14%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
iShares Russell 2000 ETF2.64%
Strategic Alternatives Fund2.61%
SmallCap Fund1.98%
Fidelity Strategic Dividend and Income Fund1.90%

OakChart. COLL. Cached 15 minutes.